84 related articles for article (PubMed ID: 3813321)
1. [Animal experiments in hospitals on the subject of addicting substances].
Olivennes A; Olivennes F
Ann Med Psychol (Paris); 1986 Feb; 144(2):184-90. PubMed ID: 3813321
[No Abstract] [Full Text] [Related]
2. [Problems in preclinical pharmacology when deciding on suitable animal species and animal tests models].
Hoefke W
Arzneimittelforschung; 1977 Feb; 27(2A):223-8. PubMed ID: 577167
[TBL] [Abstract][Full Text] [Related]
3. Animal data in perspective.
Uehleke H
Int J Clin Pharmacol; 1973 Nov; 8(3):239-43. PubMed ID: 4772084
[No Abstract] [Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic considerations for the design and screening of potential medications.
DeVane CL
NIDA Res Monogr; 1995; 149():116-29. PubMed ID: 8775838
[No Abstract] [Full Text] [Related]
5. Chemical dependence: its effect on breast milk and on the newborn.
Dye-White EE
Home Healthc Nurse; 1985; 3(6):18-20. PubMed ID: 3854028
[No Abstract] [Full Text] [Related]
6. Predicting human pharmacokinetics from preclinical data.
Poggesi I
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):100-11. PubMed ID: 14982153
[TBL] [Abstract][Full Text] [Related]
7. [The concern over better drugs].
Janssen PA
Verh K Acad Geneeskd Belg; 1982; 44(5-6):367-90. PubMed ID: 7184277
[No Abstract] [Full Text] [Related]
8. Estimation of human drug clearance using multiexponential techniques.
Goteti K; Brassil PJ; Good SS; Garner CE
J Clin Pharmacol; 2008 Oct; 48(10):1226-36. PubMed ID: 18559487
[TBL] [Abstract][Full Text] [Related]
9. College on Problems of Drug Dependence policy on administering drugs with abuse potential in human research.
College on Problems of Drug Dependence
IRB; 1996; 18(5):5-7. PubMed ID: 11654740
[No Abstract] [Full Text] [Related]
10. Introduction: Human metabolites in safety testing (MIST) issue.
Guengerich FP
Chem Res Toxicol; 2009 Feb; 22(2):237-8. PubMed ID: 19216576
[No Abstract] [Full Text] [Related]
11. [Use of cinematography in the primary evaluation of pharmacologically-active substances].
Sardi B; Viganò V
Boll Chim Farm; 1980 Feb; 119(2):73-7. PubMed ID: 7459031
[No Abstract] [Full Text] [Related]
12. Transgenic analysis of human drug-metabolizing enzymes: preclinical drug development and toxicology.
Henderson CJ; Wolf CR
Mol Interv; 2003 Sep; 3(6):331-43. PubMed ID: 14993465
[No Abstract] [Full Text] [Related]
13. The silent treatment.
Smith C
Nature; 2003 Mar; 422(6929):342. PubMed ID: 12646928
[No Abstract] [Full Text] [Related]
14. Drug target validation: Hitting the target.
Smith C
Nature; 2003 Mar; 422(6929):341, 343, 345 passim. PubMed ID: 12646927
[No Abstract] [Full Text] [Related]
15. Some ethical issues associated with HIV vaccine trials.
Novick A
AIDS Public Policy J; 1988; 3(3):46-8. PubMed ID: 11650102
[No Abstract] [Full Text] [Related]
16. Tolerance to, and dependence on, some non-opiate psychotropic drugs.
Kalant H; LeBlanc AE; Gibbins RJ
Pharmacol Rev; 1971 Sep; 23(3):135-91. PubMed ID: 4398655
[No Abstract] [Full Text] [Related]
17. Species differences as a consideration in drug therapy.
J Am Vet Med Assoc; 1979 Nov; 175(9):1014-5. PubMed ID: 521363
[No Abstract] [Full Text] [Related]
18. Animal experimentation: a rational approach towards drug development.
Kumar V; Singh PN; Mishra B
Indian J Exp Biol; 2000 Jun; 38(6):540-8. PubMed ID: 11116523
[TBL] [Abstract][Full Text] [Related]
19. Problems associated with the screening of drugs for possible teratogenic activity.
Palmer AK
Exp Embryol Teratol; 1974; 1(0):16-33. PubMed ID: 4464051
[No Abstract] [Full Text] [Related]
20. [Drug dosage optimization taking into account human circadian rhythms].
Kudrin AN; Davydova ON; Zatsepilova TA; Riazhenov VV
Sov Med; 1985; (10):37-41. PubMed ID: 3909447
[No Abstract] [Full Text] [Related]
[Next] [New Search]
